Comparison of Serum Dkk1 (Dickkopf-1) and Bone Mineral Density in Patients on Bisphosphonate Treatment Vs no Treatment

Memon, Adeel R.; Butler, Joseph S.; O'Riordan, Michael V.; Guerin, Elizabeth; Dimitrov, Borislav D.; Harty, James

doi:10.1016/j.jocd.2012.07.003

Cited by 9 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the elevation of uric acid is not always increase DKK-1 level, as in case 4. This is because of other factors such as risedronate which had effect in reducing DKK-1 (Memon, et al, 2013). Furthermore, in case 5 (without paricalcitol group) patient has history of gastro-esophageal reflux disease (GERD) with administration of cisapride that may reduce DKK-1 (Storr, et al, 2000;Lyrus, et al, 2014).…”

Section: Resultsmentioning

confidence: 99%

Paricalcitol For CKD-MBD Associated With Secondary Hyperparathyroidism: A Case Series Focus On TRAP5b, b-ALP, and DKK-1

Suprapti

Hartono

Iqbal

et al. 2019

Indonesian J. Pharm.

View full text Add to dashboard Cite

Chronic kidney disease (CKD) lead to secondary hyperparathyroidism (sHPT) that caused by phosphate retention and hypocalcemia. This condition known as mineral and bone disorder (CKD-MBD). The increase in parathyroid hormone would increase bone turnover that result in an increased risk of bone fractures, and vascular calcification. These will increase the levels of tartrate-resistant acid phosphatase 5b (TRAP5b), and bone-specific alkaline phosphatase (b-ALP), which is a marker of bone turnover, and also dickkopfrelated protein 1 (DKK-1), which is an inhibitor of the Wnt pathway. Secondary hyperparathyroidism in CKD also caused by calcitriol deficiency. Paricalcitol is a synthetic calcitrol analogue used to reduce parathyroid hormone (iPTH) with minimal calcemic and phosphatemic activity. Vitamin D receptor activation by paricalcitol will decrease TRAP5b, b-ALP, and DKK-1. In this study we reported 9 cases of CKD-MBD with Hemodialysis (HD) and associated with sHPT. Four of nine cases received 5μg paricalcitol every HD (twice a week) while the others five is not. Level of iPTH, phosphate, calcium, TRAP5b, b-ALP, and DKK-1 were measured before initiation of study and after three months treatment. According to this study, the paricalcol administration suppresses the increase in iPTH level, bone turnover and vascular calcification showed by decreasing or supresses the increase b-ALP, TRAP5b, DKK-1 leves without increasing calcium and phosphate levels.

show abstract

Section: Resultsmentioning

confidence: 99%

Paricalcitol For CKD-MBD Associated With Secondary Hyperparathyroidism: A Case Series Focus On TRAP5b, b-ALP, and DKK-1

Suprapti

Hartono

Iqbal

et al. 2019

Indonesian J. Pharm.

View full text Add to dashboard Cite

show abstract

“…The accumulated β‐catenin translocates into the nucleus and induces the expression of OPG to inhibit receptor activator of nuclear factor κ B‐RANK‐ligand‐mediated (RANK‐RANKL) osteoclastogenesis . Although the modulation of Wnt inhibitors following either anti‐osteoporotic drugs such as raloxifene , teriparatide and bisphosphonates or pro‐osteoporotic treatments such as glucocorticoids has been reported, their possible modulation in AEDs‐associated bone loss has not been studied. This study has provided first evidence of any such association between wnt inhibitors and anti‐epileptic therapy.…”

mentioning

confidence: 99%

A Cross‐Sectional Study to Assess the Modulation of Wnt Inhibitors following Anti‐Epileptic Drug Therapy and their Correlation with Vitamin D and Receptor Activator of Nuclear Factor κ B Ligand in Indian Women with Epilepsy

Parveen

Tripathi

Vohora

2018

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Long-term anti-epileptic drug (AED) therapy compromises bone health. Although vitamin D deficiency is proposed to be involved, it alone is not held responsible. This accounts for investigating other mechanisms in bone accrual. Recent studies have shown modulation of inhibitors of wnt pathway, sclerostin and dickkopf-1 (DKK-1), in glucocorticoids-induced osteoporosis. We investigated whether AED monotherapy modulates wnt inhibitors in Indian women with epilepsy. Women of age > 20-40 years with the diagnosis of epilepsy and receiving AEDs (carbamazepine, valproate and levetiracetam) for at least a year were enrolled. The results were compared with age-matched healthy controls with no evidence of metabolic bone disease. Women undergoing treatment with AEDs (mean duration: 50.59 ± 37.929 months) exhibited higher serum sclerostin and receptor activator of nuclear factor κ B ligand (RANKL) and lower vitamin D (25-hydroxy vitamin D) and DKK-1 levels when compared to age-matched healthy controls. Sclerostin showed a positive correlation with RANKL, while DKK-1 presented no such relationship. However, no association was evident after adjusting for age, duration of treatment and total daily dose. Although a correlation between wnt inhibitors and RANKL could not be obtained, AEDs displayed changes in serum levels of wnt inhibitors in persons with epilepsy and hence these drugs may compromise bone health through a disturbance in wnt signalling mechanisms.

show abstract

Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease

et al. 2016

View full text Add to dashboard Cite

Thalassemia-associated osteoporosis constitutes a major complication in patients with thalassemia. This review presents the existing studies on the treatment of thalassemia-associated osteoporosis and discusses the management of this debilitating complication. A brief presentation of the disease characteristics and pathogenetic mechanisms is also provided. The life expectancy of patients with thalassemia has increased markedly in recent years resulting in the aging of the population and the emergence of new comorbidities. The majority of patients with thalassemia have low bone mineral density and experience lifelong fracture rates as high as 71 %. The pathogenesis of thalassemia-associated osteoporosis (TAO) is multifactorial with anemia and iron overload playing crucial role in its development. Data concerning the prevention and treatment of TAO are extremely limited. We performed a literature research in Pubmed and Scopus to identify interventional studies evaluating the effects of various agents on TAO. Seventeen studies were retrieved. We present the results of these studies as well as a brief overview of TAO including presentation, pathogenesis, and management. Most of the studies identified are of poor quality, are not randomized controlled, and include small number of participants. There are no data concerning effects on fracture rates. Bisphosphonates are the most widely studied agents and among them zoledronic acid is the most well studied. Hormone replacement treatment (HRT) shows beneficial but small effects. Denosumab and strontium ranelate have each been evaluated in only a single study, while there are no data about the effects of anabolic agents. Given the increased life expectancy and the increase in fracture rates with age, more data about the management of TAO are warranted. Moreover, due to the need for lifelong management starting at young age, careful treatment plans which may include sequential treatment may often be required. However, currently, there are no relevant data available.

show abstract

Comparison of Serum Dkk1 (Dickkopf-1) and Bone Mineral Density in Patients on Bisphosphonate Treatment Vs no Treatment

Cited by 9 publications

References 31 publications

Paricalcitol For CKD-MBD Associated With Secondary Hyperparathyroidism: A Case Series Focus On TRAP5b, b-ALP, and DKK-1

Paricalcitol For CKD-MBD Associated With Secondary Hyperparathyroidism: A Case Series Focus On TRAP5b, b-ALP, and DKK-1

A Cross‐Sectional Study to Assess the Modulation of Wnt Inhibitors following Anti‐Epileptic Drug Therapy and their Correlation with Vitamin D and Receptor Activator of Nuclear Factor κ B Ligand in Indian Women with Epilepsy

Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease

Contact Info

Product

Resources

About